Diagnosis, Therapy, and Prognosis for Hepatocellular Carcinoma.
作者信息
Ren Zhigang, Ma Xiaochao, Duan Zhenfeng, Chen Xinhua
机构信息
Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
University of Pittsburgh, Pennsylvania, USA.
出版信息
Anal Cell Pathol (Amst). 2020 Feb 3;2020:8157406. doi: 10.1155/2020/8157406. eCollection 2020.
Abstract
摘要
相似文献
1
Diagnosis, Therapy, and Prognosis for Hepatocellular Carcinoma.肝细胞癌的诊断、治疗与预后
Anal Cell Pathol (Amst). 2020 Feb 3;2020:8157406. doi: 10.1155/2020/8157406. eCollection 2020.
2
Diagnosis and management of carcinoma of the liver.肝癌的诊断与治疗
J Am Med Womens Assoc (1972). 1984 Jul-Aug;39(4):129-32.
3
[Hepatocellular carcinoma: diagnosis and multi-modality therapy].[肝细胞癌：诊断与多模态治疗]
Internist (Berl). 1997 Oct;38(10):954-62. doi: 10.1007/s001080050106.
4
Molecular signature of hepatocellular carcinoma, hope or hype in prognosis and therapy.肝细胞癌的分子特征：预后与治疗中的希望还是炒作？
Semin Cancer Biol. 2011 Feb;21(1):1-3. doi: 10.1016/j.semcancer.2011.01.003. Epub 2011 Feb 3.
5
Primary hepatocellular carcinoma: early diagnosis and importance of screening.原发性肝细胞癌：早期诊断及筛查的重要性
N Z Med J. 1995 May 10;108(999):175-6.
6
Hepatocellular carcinoma: diagnosis, management, and prognosis.肝细胞癌：诊断、管理与预后
Surg Oncol Clin N Am. 2014 Apr;23(2):289-311. doi: 10.1016/j.soc.2013.10.006. Epub 2013 Dec 7.
7
8
[Strengthening to diagnosis and treatment of hepatocellular carcinoma].[加强肝细胞癌的诊断与治疗]
Zhonghua Yi Xue Za Zhi. 2007 Aug 14;87(30):2089-91.
9
[Changed diagnosis and treatment in hepatocellular carcinoma].[肝细胞癌诊断与治疗的变化]
Ned Tijdschr Geneeskd. 1996 Aug 3;140(31):1618.
10
Endoscopic diagnosis and therapy of hepatocellular carcinoma.肝细胞癌的内镜诊断与治疗
Endoscopy. 1993 Jan;25(1):126-30. doi: 10.1055/s-2007-1010270.
引用本文的文献
1
Stemness-hypoxia genes , , and are associated with prognosis and tumor immune microenvironment in hepatocellular carcinoma.干性缺氧基因、和与肝细胞癌的预后及肿瘤免疫微环境相关。
Transl Cancer Res. 2025 Jul 30;14(7):4009-4023. doi: 10.21037/tcr-24-2030. Epub 2025 Jul 25.
2
Circ_0008043 promotes the metastasis of hepatocellular carcinoma by regulating the miR-661/PLEKHG4B axis.环状RNA_0008043通过调控miR-661/PLEKHG4B轴促进肝细胞癌的转移。
Sci Rep. 2025 Jul 8;15(1):24580. doi: 10.1038/s41598-025-10618-6.
3
miR‑100: A key tumor suppressor regulatory factor in human malignant tumors (Review).微小RNA-100：人类恶性肿瘤中的关键抑癌调节因子（综述）
Int J Mol Med. 2025 Apr;55(4). doi: 10.3892/ijmm.2025.5508. Epub 2025 Feb 28.
4
Efficacy of sorafenib combined with transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma: A meta-analysis.索拉非尼联合经动脉化疗栓塞术治疗晚期肝细胞癌的疗效：一项荟萃分析。
World J Gastrointest Oncol. 2025 Feb 15;17(2):98927. doi: 10.4251/wjgo.v17.i2.98927.
5
GGCT participates in the malignant process of hepatocellular cancer cells by regulating the PTEN/PI3K/AKT pathway through binding to EZH2.GGCT通过与EZH2结合来调节PTEN/PI3K/AKT通路，从而参与肝癌细胞的恶性进程。
Discov Oncol. 2025 Feb 7;16(1):129. doi: 10.1007/s12672-025-01882-z.
6
The therapeutic role of naringenin nanoparticles on hepatocellular carcinoma.柚皮素纳米颗粒对肝细胞癌的治疗作用。
BMC Pharmacol Toxicol. 2025 Jan 3;26(1):3. doi: 10.1186/s40360-024-00823-w.
7
M2-polarized tumor-associated macrophage-secreted exosomal lncRNA NEAT1 upregulates galectin-3 by recruiting KLF5 and promotes HCC immune escape.M2极化的肿瘤相关巨噬细胞分泌的外泌体长链非编码RNA NEAT1通过招募KLF5上调半乳糖凝集素-3并促进肝癌免疫逃逸。
J Cell Commun Signal. 2024 Dec 23;19(1):e12060. doi: 10.1002/ccs3.12060. eCollection 2025 Mar.
8
The influence of biophysical niche on tumor-associated macrophages in liver cancer.生物物理生态位对肝癌相关巨噬细胞的影响。
Hepatol Commun. 2024 Oct 30;8(11). doi: 10.1097/HC9.0000000000000569. eCollection 2024 Nov 1.
9
METTL3-mediated m6A modification of ZNF384 promotes hepatocellular carcinoma progression by transcriptionally activating ACSM1.METTL3介导的ZNF384的m6A修饰通过转录激活ACSM1促进肝细胞癌进展。
Clin Transl Oncol. 2025 May;27(5):2256-2268. doi: 10.1007/s12094-024-03701-3. Epub 2024 Sep 29.
10
Advances and challenges of exosome-derived noncoding RNAs for hepatocellular carcinoma diagnosis and treatment.外泌体来源的非编码RNA在肝细胞癌诊断与治疗中的研究进展及挑战
Biochem Biophys Rep. 2024 Mar 24;38:101695. doi: 10.1016/j.bbrep.2024.101695. eCollection 2024 Jul.
本文引用的文献
1
The gut microbiome and liver cancer: mechanisms and clinical translation.肠道微生物群与肝癌：机制及临床转化
Nat Rev Gastroenterol Hepatol. 2017 Sep;14(9):527-539. doi: 10.1038/nrgastro.2017.72. Epub 2017 Jul 5.
2
Patients with early recurrence of hepatocellular carcinoma have poor prognosis.肝细胞癌早期复发的患者预后较差。
Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):279-288. doi: 10.1016/s1499-3872(16)60181-9.
3
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
4
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
5
What is the long-term outcome of the liver allograft?肝移植的长期预后如何？
J Hepatol. 2011 Sep;55(3):702-717. doi: 10.1016/j.jhep.2011.03.005. Epub 2011 Mar 21.
Zotero 插件